SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: TREND1, conix, $Pistol Pete$, MANOLO1775
Search This Board:
Last Post: 12/6/2016 2:03:26 PM - Followers: 357 - Board type: Free - Posts Today: 8


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MNKD News: Current Report Filing (8-k) 11/14/2016 08:05:55 AM
MNKD News: MannKind and Sanofi Reach Agreement on AFREZZA® 11/09/2016 07:38:02 PM
MNKD News: Current Report Filing (8-k) 11/09/2016 05:10:46 PM
MNKD News: Quarterly Report (10-q) 11/09/2016 09:00:14 AM
MNKD News: MannKind Corporation Reports 2016 Third Quarter Financial Results 11/09/2016 08:30:00 AM
#19954  Sticky Note MannKind and Sanofi Reach Agreement on AFREZZA® MANOLO1775 11/10/16 02:10:38 PM
#19634  Sticky Note $MNKD MannKind Is 'Making Progress' On Its Alternative $Pistol Pete$ 08/30/16 04:46:19 PM
#20081   After a 2.5 year break back on board thexsandos 12/06/16 02:03:26 PM
#20080   Motley Fool had a hit piece this morning, Hypi 12/06/16 02:02:03 PM
#20079   I'm on board. Let's go ManKind!!! beginneer 12/06/16 01:54:36 PM
#20078   MNKD 0.6544. TheLionAndTheLamb 12/06/16 12:52:14 PM
#20077   MNKD $ 0.6418 a big break here psar TheLionAndTheLamb 12/06/16 12:45:01 PM
#20076   Pretty obvious that news is on the way Hypi 12/06/16 11:17:18 AM
#20075   MNKD $ 0.62. TheLionAndTheLamb 12/06/16 11:07:56 AM
#20074   $MNKD: Back to basics post, mc67 12/06/16 09:07:38 AM
#20073   Perfect place for an add. Looks great. tyfoidhana 12/05/16 10:33:49 PM
#20072!page3 Hypi 12/05/16 08:07:31 PM
#20071   I'm going to get excited here about the tyfoidhana 12/05/16 07:54:24 PM
#20070   Good two day move with nice volume on Hypi 12/05/16 04:41:30 PM
#20069   Interesting conspiracy analysis, but also what might be Hypi 12/03/16 01:19:42 PM
#20068   * * $MNKD Video Chart 12-02-16 * * ClayTrader 12/02/16 04:42:07 PM
#20067   A bit above $ 0.55 would be nice, TheLionAndTheLamb 12/02/16 03:54:51 PM
#20066   Unfortunately, the stock is highly and easily manipulated, Hypi 12/02/16 03:53:12 PM
#20065   MNKD $ 0.5632. It needs a close TheLionAndTheLamb 12/02/16 03:45:37 PM
#20064   Good volume which is nice to see. Somebody Hypi 12/02/16 03:43:04 PM
#20063   MNKD $ 0.60. TheLionAndTheLamb 12/02/16 02:44:55 PM
#20062   JMHO but I think we will see a Hypi 12/02/16 01:45:45 PM
#20061   MNKD $ 0.5521 perhaps we have that breakout now. TheLionAndTheLamb 12/02/16 11:45:47 AM
#20060   MNKD $ 0.5299. Thanks for the write TheLionAndTheLamb 12/02/16 11:00:42 AM
#20059   First VDEX center officially opened this week and Hypi 12/02/16 10:57:28 AM
#20058   MNKD $ 0.536. TheLionAndTheLamb 12/02/16 10:26:03 AM
#20057   MNKD $ 0.50 ready to make it's move perhaps. TheLionAndTheLamb 12/02/16 10:19:04 AM
#20056   EpiPen maker still doesn't get it Hypi 12/01/16 07:44:27 PM
#20055   $MNKD 15' Chart $Pistol Pete$ 11/30/16 12:40:36 PM
#20054   MNKD DAY TREND1 11/29/16 12:53:12 PM
#20053   MNKD $ 0.5012. No idea but it TheLionAndTheLamb 11/29/16 12:47:28 PM
#20052   QUOTE MNKD 0.537 gap filled on daily chart from TREND1 11/29/16 12:44:28 PM
#20051   ..could be people moving $$ into MJ plays.. mc67 11/28/16 03:01:29 PM
#20050   Hope so...has a hard dump today... to 51's bobl17211 11/28/16 09:53:35 AM
#20049   MNKD 0.537 gap filled on daily chart from TheLionAndTheLamb 11/23/16 02:47:56 PM
#20048   $MNKD Moving Average MA(100) @ $.76 and MA( $Pistol Pete$ 11/23/16 02:55:55 AM
#20047   $MNKD Daily and Weekly Chart $Pistol Pete$ 11/22/16 01:35:04 AM
#20046   I ASKED HIM ABOUT 288 TREND1 11/18/16 10:18:33 PM
#20045   I SEE YOUR POINT TREND1 11/18/16 10:11:34 PM
#20044   risingskepticism FROM SA WHS 11/18/16 09:59:56 PM
#20043   I get info from SA TREND1 11/18/16 09:48:06 PM
#20042   Please give the link WHS 11/18/16 09:19:28 PM
#20041   risingskepticism FROM SA TREND1 11/18/16 11:44:22 AM
#20040   7-9 months, the script (200-300) = (mnkd card WHS 11/17/16 10:06:57 PM
#20039   I don't think MNKD is using the ATM. Aloha96707 11/17/16 04:58:08 PM
#20038   Does he take A1C every 4 months ? TREND1 11/17/16 01:53:41 PM
#20037   I agree but how many free samples and Hypi 11/17/16 01:48:50 PM
#20036   MNKD reported income for the quarter and I TREND1 11/17/16 12:57:49 PM
#20035   Also many people having been saying this and Hypi 11/17/16 12:48:45 PM
#20034   We have seen the lows and too much Hypi 11/17/16 12:12:55 PM
#20033   Well I guess we have to wait and see! Aloha96707 11/17/16 01:04:19 AM
#20032   quote I'm expecting an RLS milestone payment of $25M TREND1 11/16/16 04:10:02 PM